0000899243-18-025797.txt : 20181002
0000899243-18-025797.hdr.sgml : 20181002
20181002163059
ACCESSION NUMBER: 0000899243-18-025797
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181001
FILED AS OF DATE: 20181002
DATE AS OF CHANGE: 20181002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Perkins Adelene Q
CENTRAL INDEX KEY: 0001375124
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31141
FILM NUMBER: 181101710
MAIL ADDRESS:
STREET 1: C/O INFINITY PHARMACEUTICALS, INC.
STREET 2: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001113148
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330655706
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6174531000
MAIL ADDRESS:
STREET 1: 784 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/
DATE OF NAME CHANGE: 20060913
FORMER COMPANY:
FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC
DATE OF NAME CHANGE: 20000428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-01
0
0001113148
INFINITY PHARMACEUTICALS, INC.
INFI
0001375124
Perkins Adelene Q
C/O INFINITY PHARMACEUTICALS, INC.
784 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
1
1
0
0
Chief Executive Officer
Common Stock
2018-10-01
4
S
0
5000
2.82
D
609561
D
Common Stock
16446.7945
I
401(K)
The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.
The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.80 to $2.88, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
Includes 7,309 shares of common stock acquired by Ms. Perkins on June 16, 2018 through participation in the issuer's Employee Stock Purchase Plan.
/s/ Adelene Perkins
2018-10-02